Grail (GRAL) news
Recent news
Grail's Galleri test to face FDA advisory panel Sept. 23
AInvest Wire · Aug 7, 2026Canaccord Genuity raises target price to $105 from $100
Canaccord Genuity has raised its price target for GRAIL, Inc. (NASDAQ: GRAL) to $105.00 from $85.00, while maintaining a Buy rating on the stock. This adjustment follows significant progress in the adoption and reimbursement of GRAIL’s Galleri multi-cancer early detection (MCED) test. The company’s…
AInvest Wire · Aug 5, 2026Grail Inc: Mizuho raises target price to $65 from $58
AInvest Wire · Jul 15, 2026Grail completes $110M equity financing with Samsung entities
Samsung C&T (SCT) and Samsung Electronics (SEC) have completed a $110 million equity investment in GRAIL , a healthcare company focused on early cancer detection, at a price of $70.05 per share of common stock. The investment, which was announced in late 2025 and finalized in early 2026, is part of…
AInvest Wire · Jun 25, 2026Grail completes $110 million equity financing with Samsung entities
AInvest Wire · Jun 25, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.